SCHEMBL5482312

SCHEMBL5482312

Cc1cc(F)cc2c1NC(=O)C2(c1ccc(O)cc1)c1ccc(O)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 3/20 0.63
GPR55 Q9Y2T6 3/20 0.63
HTT P42858 1/20 0.63
GPR35 Q9HC97 1/20 0.63
CHRM2 P08172 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
KCNH2 Q12809 1/20 0.47
MAPT P10636 3/20 0.41
KMT2A Q03164 2/20 0.41
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.41
XBP1 P17861 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
PKM P14618 1/20 0.41
MMP2 P08253 1/20 0.37
MMP9 P14780 1/20 0.37
POLB P06746 1/20 0.34
CASP6 P55212 1/20 0.34
HCRTR1 O43613 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5486626 0.87 GPR55 (0.68) CNR1GPR55HTTGPR35CHRM2
SCHEMBL5474347 0.85 CNR1 (0.67) CNR1GPR55HTTGPR35CHRM2
SCHEMBL5488424 0.85 CNR1 (0.51) CNR1GPR55HTTGPR35CHRM2
SCHEMBL5483376 0.83 CNR1 (0.50) CNR1GPR55HTTGPR35CHRM2
SCHEMBL5486000 0.83 CNR1 (0.63) CNR1GPR55HTTGPR35CHRM2
SCHEMBL5486611 0.83 CNR1 (0.63) CNR1GPR55HTTGPR35CHRM2
SCHEMBL5483069 0.81 CNR1 (0.60) CNR1GPR55HTTGPR35CHRM2
SCHEMBL5478375 0.78 GPR55 (1.00) CNR1GPR55HTTGPR35CHRM2
SCHEMBL29443920 0.78 GPR55 (1.00) CNR1GPR55HTTGPR35CHRM2
SCHEMBL3080833 0.77 CNR1 (0.41) CNR1GPR55HTTGPR35KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 CNR1 973/4885GPR55 2338/4885HTT 1880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.